Ibrahim T Aldoss

Trials

Studies that name Ibrahim T Aldoss as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:42 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05157971 · Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

  City of Hope Medical Center · active not recruiting · B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia · principal investigator
• Ph1
  NCT04681105 · Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

  City of Hope Medical Center · completed · Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• BAFF-R CAR T cell therapy for ALL
  R01CA269569 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2022 to 2026 · $677,623 awarded in 2026
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Leadership, Planning and Evaluation
  P30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2004 to 2026
  Named on NCT05157971, NCT04681105